



Provider Notice 12-91

Dear Provider,

The Health Care Authority (Agency) will implement the following changes to the Prescription Drug Program:

1. New additions to the Maximum Allowable Cost (MAC) list
2. MAC adjustments
3. MAC deletions

MAC Additions			
Generic Name	Strength	Form	MAC Effective 12/01/12
METHYLPHENIDATE HCL	10MG	CAPSULE CR	\$4.31150
METHYLPHENIDATE HCL	20MG	CAPSULE CR	\$4.31150
METHYLPHENIDATE HCL	30MG	CAPSULE CR	\$4.31150
METHYLPHENIDATE HCL	40MG	CAPSULE CR	\$5.91650
METHYLPHENIDATE HCL	50MG	CAPSULE CR	\$7.26970
METHYLPHENIDATE HCL	60MG	CAPSULE CR	\$7.26970
PIOGLITAZONE HCL	15MG	TABLET	\$2.87540
PIOGLITAZONE HCL	30MG	TABLET	\$4.22340
PIOGLITAZONE HCL	45MG	TABLET	\$4.69610

CLOTRIMAZOLE/BETAMETHASONE (15GM SIZE)	1-0.05%	CREAM	\$1.21066
CLOTRIMAZOLE/BETAMETHASONE (45GM SIZE)	1-0.05%	CREAM	\$0.94660
ESCITALOPRAM OXALATE	5MG	TABLET	\$0.17883

MAC Adjustments			
Generic Name	Strength	Form	MAC Effective 12/01/12
ESCITALOPRAM OXALATE	10MG	TABLET	\$0.18527
ESCITALOPRAM OXALATE	20MG	TABLET	\$0.19460
EXEMESTANE	25MG	TABLET	\$5.30320
GABAPENTIN	600MG	TABLET	\$0.31670
GABAPENTIN	800MG	TABLET	\$0.40700
METHOTREXATE	2.5MG	TABLET	\$0.80910
ONDANSETRON HCL	4MG	TABLET	\$0.15866
ONDANSETRON HCL	8MG	TABLET	\$0.19866
SUMATRIPTAN SUCCINATE	25MG	TABLET	\$1.02332
SUMATRIPTAN SUCCINATE	50MG	TABLET	\$1.02332
SUMATRIPTAN SUCCINATE	100MG	TABLET	\$1.10554
ZIPRASIDONE HCL	20MG	CAPSULE	\$3.04040
ZIPRASIDONE HCL	40MG	CAPSULE	\$3.04040
ZIPRASIDONE HCL	60MG	CAPSULE	\$3.58660
ZIPRASIDONE HCL	80MG	CAPSULE	\$3.58660

OXAZEPAM	10MG	CAPSULE	\$0.00000
MAC Deletions			
Generic Name	Strength	Form	MAC Effective 12/01/12

Thank you.

BC/AL
 Provider Publications Team
 Medicaid Program
 Health Care Authority

NOTE: Please do not reply directly to this Listserv message as it is not monitored. If you have feedback or questions, please select one of the options at <http://hrsa.dshs.wa.gov/contact/default.aspx>. Your message will be delivered to the appropriate staff member.

NOTICE: This message (including any attachments) may contain information that is privileged, confidential, proprietary and/or otherwise protected from disclosure to anyone other than its intended recipient(s). Any dissemination, copying, retention or use of this message or its contents (including any attachments) by persons other than the intended recipient(s) is strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail or telephone and permanently delete all copies of this message and any attachments. Thank you for your cooperation.